Challenges in IBD Research: Precision Medicine.

Precision medicine is part of five focus areas of the Challenges in IBD research document, which also includes preclinical human IBD mechanisms, environmental triggers, novel technologies, and pragmatic clinical research. The Challenges in IBD Research document provides a comprehensive overview of current gaps in inflammatory bowel diseases (IBD) research and delivers actionable approaches to address them. It is the result of a multidisciplinary input from scientists, clinicians, patients, and funders, and represents a valuable resource for patient centric research prioritization. In particular, the precision medicine section is focused on highlighting the main gap areas that must be addressed to get closer to treatments tailored to the biological and clinical characteristics of each patient, which is the aim of precision medicine. The main gaps were identified in: 1) understanding and predicting the natural history of IBD: disease susceptibility, activity, and behavior; 2) predicting disease course and treatment response; and 3) optimizing current and developing new molecular technologies. Suggested approaches to bridge these gaps include prospective longitudinal cohort studies to identify and validate precision biomarkers for prognostication of disease course, and prediction and monitoring of treatment response. To achieve this, harmonization across studies is key as well as development of standardized methods and infrastructure. The implementation of state-of-the-art molecular technologies, systems biology and machine learning approaches for multi-omics and clinical data integration and analysis will be also fundamental. Finally, randomized biomarker-stratified trials will be critical to evaluate the clinical utility of validated signatures and biomarkers in improving patient outcomes and cost-effective care.

[1]  R. Owens,et al.  Oncostatin M drives intestinal inflammation in mice and its abundance predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease , 2017, Nature Medicine.

[2]  J. Faith,et al.  Challenges in IBD Research: Preclinical Human IBD Mechanisms. , 2019, Inflammatory bowel diseases.

[3]  J. Satsangi,et al.  Biomarkers in Search of Precision Medicine in IBD , 2016, The American Journal of Gastroenterology.

[4]  Samir A. Shah,et al.  Serum Proteome Profiles in Stricturing Crohn's Disease: A Pilot Study , 2015, Inflammatory bowel diseases.

[5]  L. Peyrin-Biroulet,et al.  Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases. , 2017, Gastroenterology.

[6]  Manolis Kellis,et al.  Challenges in IBD Research: Environmental Triggers. , 2019, Inflammatory bowel diseases.

[7]  H. Uhlig,et al.  Clinical Genomics in Inflammatory Bowel Disease. , 2017, Trends in genetics : TIG.

[8]  G Van Assche,et al.  Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis , 2009, Gut.

[9]  Timothy L. Tickle,et al.  Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. , 2014, The Journal of clinical investigation.

[10]  D. Iliopoulos,et al.  The IBD interactome: an integrated view of aetiology, pathogenesis and therapy , 2017, Nature Reviews Gastroenterology & Hepatology.

[11]  Andrea Califano,et al.  Predicting Drug Response in Human Prostate Cancer from Preclinical Analysis of In Vivo Mouse Models. , 2015, Cell reports.

[12]  D. Greco,et al.  Targeted Analysis of Serum Proteins Encoded at Known Inflammatory Bowel Disease Risk Loci , 2018, Inflammatory bowel diseases.

[13]  Frank I. Scott,et al.  Challenges in IBD Research: Pragmatic Clinical Research. , 2019, Inflammatory bowel diseases.

[14]  M. Cvancarova,et al.  Risk matrix model for prediction of colectomy in a population-based study of ulcerative colitis patients (the IBSEN study) , 2015, Scandinavian journal of gastroenterology.

[15]  Mary E. Haas,et al.  Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations , 2018, Nature Genetics.

[16]  M. Dubinsky,et al.  Real‐time tool to display the predicted disease course and treatment response for children with Crohn's disease , 2011, Inflammatory bowel diseases.

[17]  Stanley B. Cohen,et al.  Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease. , 2014, Gastroenterology.

[18]  Judy H. Cho,et al.  Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study , 2017, The Lancet.

[19]  U. Vogel,et al.  Systematic review: genetic biomarkers associated with anti‐TNF treatment response in inflammatory bowel diseases , 2016, Alimentary pharmacology & therapeutics.

[20]  James M. Dahlhamer,et al.  Prevalence of Inflammatory Bowel Disease Among Adults Aged ≥18 Years - United States, 2015. , 2016, MMWR. Morbidity and mortality weekly report.

[21]  M. Vatn,et al.  Risk Matrix for Prediction of Advanced Disease in a Population-based Study of Patients with Crohn's Disease (the IBSEN Study) , 2014, Inflammatory bowel diseases.

[22]  T. Lu,et al.  Challenges in IBD Research: Novel Technologies. , 2019, Inflammatory bowel diseases.

[23]  P. Rutgeerts,et al.  A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[24]  Miles Parkes,et al.  Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. , 2011, The Journal of clinical investigation.

[25]  B. Psaty,et al.  Genetic predictors of medically refractory ulcerative colitis , 2010, Inflammatory bowel diseases.

[26]  M. Bechtold,et al.  pANCA Positivity Predicts Lower Clinical Response to Infliximab Therapy among Patients with IBD , 2015, Southern medical journal.

[27]  Kristel Van Steen,et al.  Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease‡ , 2010, Inflammatory bowel diseases.

[28]  A. Griffiths,et al.  Factors associated with early outcomes following standardized therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study , 2017, The lancet. Gastroenterology & hepatology.

[29]  S. Targan,et al.  Molecular Patterns in Human Ulcerative Colitis and Correlation with Response to Infliximab , 2014, Inflammatory bowel diseases.

[30]  C. Klein,et al.  The diagnostic approach to monogenic very early onset inflammatory bowel disease. , 2014, Gastroenterology.

[31]  E. Loftus,et al.  Incidence and Prevalence of Crohn’s Disease and Ulcerative Colitis in Olmsted County, Minnesota From 1970 Through 2010 , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[32]  B. Ye,et al.  Development of a Novel Predictive Model for the Clinical Course of Crohn's Disease: Results from the CONNECT Study , 2017, Inflammatory bowel diseases.